A Phase II Study of Sorafenib With Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Sorafenib (Primary) ; Epirubicin; Ifosfamide
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 27 Jun 2018 Planned End Date changed from 1 Oct 2017 to 31 Dec 2018.
- 27 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.